Atlas Energy Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark Alan Hodgson
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 202, 1201-5th Street SW Calgary AB Canada T2R 0Y6
- IPO Date
- Jan 8, 2021
- Website
- atlas-corp.ca
- Similar Companies
- Business
- Atlas Energy Corp. (TSXV:ATLE; OTC:CANSF) is a Calgary-based international upstream oil and gas royalty and streaming company that acquires, manages and monetizes a diversified portfolio of royalty and streaming interests in upstream oil and gas assets across global markets. The company provides non-dilutive financing to operators through revenue- or production-based royalties and streams, enabling project development, acquisitions, exploration, appraisal and balance sheet strengthening; it targets deal sizes of US$25-50 million in top-tier assets operated by industry leaders in dynamic basins worldwide, including potential North American opportunities. Founded in 2019 and headquartered at 202, 1201-5th Street SW, Calgary, Alberta, Canada T2R 0Y6, Atlas employs a team of upstream professionals with experience across more than 70 countries and over US$19 billion in completed M&A and finance transactions. In June 2025, the company underwent a transformative recapitalization, completing a $30 million non-brokered equity private placement, appointing a new executive team led by President and CEO Mark Hodgson and reconstituting its board of directors, changing its name from Willow Biosciences Inc., consolidating shares on a one-for-five basis, transitioning to TSXV Sandbox listing under ATLE and voluntarily delisting from OTCQB while maintaining OTC Pink trading.
Atlas Energy Reports First Quarter 2026 Financial Results
Atlas Energy Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Operations and Filing of Its 2025 AIF
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
WILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF SALE OF OPERATING SUBSIDIARY AND MANAGEMENT CHANGES
WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY
WILLOW ANNOUNCES INITIATION OF STRATEGIC REVIEW PROCESS
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO
Willow Biosciences announces second collaboration with leading API manufacturer
WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
Willow Biosciences inks commercial partnership with Kalsec
WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC.
Willow Biosciences CEO confident in future after record revenue and new partnerships - ICYMI
Willow Biosciences achieves record revenue for the second quarter
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Willow Biosciences lands biopesticides collaboration worth $2M in year one
Willow Biosciences lands biopesticides collaboration worth $2mln in year one
WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY
Willow Biosciences secures $1.6M for research and product development